Insider Selling: Voyager Therapeutics (NASDAQ:VYGR) COO Sells $24,346.66 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,458 shares of the company’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $3.77, for a total value of $24,346.66. Following the completion of the transaction, the chief operating officer directly owned 199,738 shares in the company, valued at approximately $753,012.26. The trade was a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robin Swartz also recently made the following trade(s):

• On Tuesday, February 10th, Robin Swartz sold 4,569 shares of Voyager Therapeutics stock. The stock was sold at an average price of $3.85, for a total value of $17,590.65.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $4.10 on Friday. The business’s 50-day simple moving average is $3.86 and its two-hundred day simple moving average is $4.12. The company has a market cap of $227.96 million, a PE ratio of -1.90 and a beta of 1.30. Voyager Therapeutics, Inc. has a fifty-two week low of $2.64 and a fifty-two week high of $5.55.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of VYGR. EcoR1 Capital LLC grew its stake in shares of Voyager Therapeutics by 497.2% during the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after purchasing an additional 3,332,544 shares during the period. Vanguard Group Inc. lifted its stake in shares of Voyager Therapeutics by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock valued at $15,178,000 after purchasing an additional 40,147 shares during the period. Opaleye Management Inc. purchased a new stake in Voyager Therapeutics during the fourth quarter worth $4,704,000. Erste Asset Management GmbH grew its position in Voyager Therapeutics by 7.0% during the fourth quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock valued at $4,718,000 after buying an additional 78,348 shares during the period. Finally, Geode Capital Management LLC grew its position in Voyager Therapeutics by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after buying an additional 11,929 shares during the period. 48.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. HC Wainwright dropped their price objective on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Finally, Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $13.75.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.